More Data Support Trodelvy-Keytruda Combo in Triple-Negative Breast Cancer

(MedPage Today) -- CHICAGO -- Sacituzumab govitecan (SG, Trodelvy) added to pembrolizumab (Keytruda) extended a surrogate measure of long-term clinical outcomes compared with chemotherapy plus pembrolizumab in patients with PD-L1-positive metastatic...
Source
MedPage Today
Opens original article in a new tab



